SEPT6-ABL2 fusion for use in the diagnosis and/or treatment of cancer

Patent number:

PCT/EP2022/065750; EP21382663

No items found.

The present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2], and also to the use of [SEPT6-ABL2] fusion in a method for the diagnosis and/or treatment of cancer.

Countries:

Spain

Regions:

Community of Madrid

Centers:

UNIVERSIDAD AUTONOMA DE MADRID, FUNDACION INSTITUTO DE INVESTI GACION SANITARIA FUNDACION JIMENEZ DIAZ

Other entities:

Sectors:

Health

Subsectors:

TRL Level:

TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

SDG03: Good health and well-being

Applications

The present invention refers to the medical field. Particularly, the present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2]. The present invention is also focused on the use of SEPT6-ABL2 fusion in a method for the diagnosis and/or treatment of cancer.

Comments

Other related patents

Health

TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS

Countries

Spain

Health

Automotive & Rail

Aerospace

Construction

SYSTEM FOR TESTING EXOSKELETONS IN A CONTROLLED ENVIRONMENT

Countries

Spain

Health

CARDIOTHORACIC SURGERY SIMULATOR

Countries

Spain

Get back to patents directory